|Day's Range||0.05 - 0.05|
|52 Week Range||0.05 - 0.14|
|PE Ratio (TTM)||-1.67|
|Earnings Date||Sep 1, 2016 - Sep 2, 2016|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||0.64|
Q1 2017 Financials: Apteryx Contributes to Revenue. LED Medical (LMD.V) (LEDIF) reported Q1 financial results on May 30th. This was the first quarter which included contribution from Apteryx, the acquisition of which closed around mid-February. While LED does not disclose revenue by segment, footnotes in the Q1 filing credit sales of Apteryx's imaging software products as partially responsible for the 12%+ growth in total revenue from Q4 2016. But despite the sequential growth, we would not characterize revenue as a particular highlight (discussed more below). On a much brighter side, however, was gross margin which apparently also benefitted from relatively high margin Apteryx-related sales and came in at the highest level since Q2 2014. Operating expenses also surprised on the upside (i.e.
VANCOUVER, BC / ACCESSWIRE / May 30, 2017 / LED Medical Diagnostics Inc. (TSX-V: LMD; OTCQB: LEDIF; FRA: LME) ("LED Medical" or the "Company") today announced its financial results ...
On the brighter side, LED’s cash balance was recently shored up via the sale of debt and equity - which happened concurrently with the Apteryx acquisition. While $7M of the ~$11M (gross U.S) raise was allocated to the acquisitions’ upfront payment, much of the remainder will be used to fund operations – presumably including to beef up their inventory (balance of which fell by a relatively large $4.9M in 2016). While we won’t know exactly what to expect in terms of margins from the company until more financial information becomes available, given that Apteryx is primarily involved in software development (i.e.